Results 1 to 10 of about 19,821,917 (190)

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation

American Journal of Medicine, 2016
Marco Zimarino, Fabrizio Ricci, Manesh Patel   +2 more
exaly  

Comparison of bleeding risks among non-vitamin K antagonist oral anticoagulants using the Korea adverse event reporting system database

Therapeutic Advances in Drug Safety, 2019
Kyounghoon Park, Young-Jin Ko, Minsuk Kim   +2 more
exaly  

Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation

Expert Opinion on Drug Metabolism and Toxicology, 2015
Qinmei Xiong, Yee C Lau
exaly  

Management of Patients on Non–Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting: A Scientific Statement From the American Heart Association

Circulation, 2017
exaly  

Non-vitamin K Antagonist Oral Anticoagulants vs. Warfarin at Risk of Fractures: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frontiers in Pharmacology, 2018
Chi Zhang, Zhichun Gu, Hou-Wen Lin
exaly  

Identifying Factors That Predict the Prescription of Non–vitamin K Antagonist Oral Anticoagulants in Older Individuals With Atrial Fibrillation

Journal of the American Medical Directors Association, 2019
Kieran L Quinn
exaly  

Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation

Journal of Market Access & Health Policy, 2019
Pierre Levy, Mondher Toumi, Kevin Bowrin   +2 more
exaly  

Non-vitamin K antagonist oral anticoagulants for heart diseases [PDF]

Терапевтический архив, 2017
Non-vitamin K antagonist oral anticoagulants (NОАСs) are highly effective drugs that prevent venous thrombosis and stroke in atrial fibrillation. Their use has difficulties that are associated with the need for laboratory control and with the influence ...
T B Kondratieva, L V Popova, I N Bokarev
doaj   +4 more sources

Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants

Clinical Interventions in Aging, 2015
Mohit K Turagam, Poonam Velagapudi, Greg C FlakerDivision of Cardiovascular Medicine, University of Missouri School of Medicine, Columbia, MO, USAAbstract: Stroke prevention in elderly atrial fibrillation patients remains a challenge.
Turagam MK, Velagapudi P, Flaker GC
doaj   +3 more sources

Non-Vitamin K Antagonist Oral Anticoagulants in Differentiated Approach to the Use in Cardiological Practice: Literature Review

Український журнал серцево-судинної хірургії, 2023
Non-vitamin K antagonist oral anticoagulants (novel oral anticoagulants, NOACs) are important pharmaceuticals for prevention of stroke and systemic embolism in non-valvular atrial fibrillation patients.
Larysa A. Vozniuk, Olga V. Dzekan, Sergii O. Siromakha   +2 more
doaj   +2 more sources